pSivida Corp. (NASDAQ:PSDV)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a research note issued to investors on Wednesday. They presently have a $5.00 price target on the stock. HC Wainwright’s target price points to a potential upside of 262.32% from the company’s previous close.
Separately, Laidlaw started coverage on pSivida Corp. in a report on Wednesday. They set a “buy” rating and a $5.00 price objective for the company. Six investment analysts have rated the stock with a buy rating, The company has a consensus rating of “Buy” and an average price target of $8.00.
pSivida Corp. (NASDAQ:PSDV) traded up $0.04 during mid-day trading on Wednesday, hitting $1.38. The stock had a trading volume of 1,258,259 shares, compared to its average volume of 497,724. pSivida Corp. has a 1-year low of $1.03 and a 1-year high of $2.45.
pSivida Corp. (NASDAQ:PSDV) last released its quarterly earnings data on Tuesday, November 7th. The company reported ($0.15) EPS for the quarter, hitting analysts’ consensus estimates of ($0.15). The business had revenue of $0.39 million during the quarter, compared to the consensus estimate of $0.74 million. pSivida Corp. had a negative return on equity of 127.88% and a negative net margin of 226.31%. research analysts predict that pSivida Corp. will post -0.59 earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: This report was first reported by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this report on another website, it was copied illegally and reposted in violation of US & international trademark & copyright legislation. The original version of this report can be accessed at https://sportsperspectives.com/2017/11/10/psivida-corp-psdv-stock-rating-reaffirmed-by-hc-wainwright.html.
A hedge fund recently bought a new stake in pSivida Corp. stock. OxFORD Asset Management LLP purchased a new position in shares of pSivida Corp. (NASDAQ:PSDV) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 69,004 shares of the company’s stock, valued at approximately $118,000. OxFORD Asset Management LLP owned about 0.18% of pSivida Corp. as of its most recent filing with the Securities and Exchange Commission (SEC). 12.99% of the stock is currently owned by hedge funds and other institutional investors.
About pSivida Corp.
pSivida Corp. develops drug delivery products primarily for the treatment of chronic eye diseases. The Company operates through the biotechnology sector segment. The Company has developed three products for treatment of back-of-the-eye diseases, which include Medidur for posterior segment uveitis, its lead product candidate that is in pivotal Phase III clinical trials; ILUVIEN for diabetic macular edema (DME), its lead licensed product that is sold in the United States and European Union (EU) countries, and Retisert.
Receive News & Ratings for pSivida Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for pSivida Corp. and related companies with MarketBeat.com's FREE daily email newsletter.